Safety of IPX066, an extended release carbidopa–levodopa formulation, for the treatment of Parkinson’s disease

Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration

(2014) Wolfgang H Jost   Expert Opinion On Drug Safety

IPX066, a mixed immediate/sustained-release levodopa preparation for Parkinson’s disease

(2014) William Ondo   EXPERT OPINION ON PHARMACOTHERAPY

Comparison of IPX066 with carbidopa–levodopa plus entacapone in advanced PD patients

(2014) Fabrizio Stocchi et al.   PARKINSONISM & RELATED DISORDERS

Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial

(2013) Robert A Hauser et al.   LANCET NEUROLOGY

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study

(2013) C Warren Olanow et al.   LANCET NEUROLOGY

Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease

(2013) Rajesh Pahwa et al.   PARKINSONISM & RELATED DISORDERS

Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease

(2011) Robert A. Hauser et al.   MOVEMENT DISORDERS

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

(2011) Susan H. Fox et al.   MOVEMENT DISORDERS

Large differences in levodopa dose requirement in Parkinson’s disease: men use higher doses than women

(2009) D. Nyholm et al.   EUROPEAN JOURNAL OF NEUROLOGY

L-dopa therapy for Parkinson's disease: Past, present, and future

(2009) Toshiharu Nagatsu et al.   PARKINSONISM & RELATED DISORDERS